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Background: HCV RNA viral load is an important predictor of sustained virological response and, recently, a significant
correlation with liver fibrosis was described. We investigated on possible influence of clinical and viro-immunological
variables on HCV viral load in HIV-HCV co-infected patients over a study time of three years (2009-2012).
Methods: We retrospectively enrolled 98 adult patients with a diagnosis of chronic HIV infection in 2009, a diagnosis of
chronic HCV infection with a detectable plasma HCV RNA in 2009 and 2012, HCV therapy-naïve or with failed and
stopped antiviral treatment before June 2008. The following variables were recorded: age, gender, HCV genotype, IL28B
rs12979860 CC genotype, HCV treatment status, advanced liver fibrosis diagnosis, antiretroviral therapy, CD4+ cell count,
HCV viral load, HIV RNA (plasma HIV-1 RNA levels were measured from blood samples every three months at least). The
correlation was established using linear regression analysis, analysis of variance and Fisher’s exact test. Comparisons
between groups were performed using Fisher’s exact test, the independent samples t-test and the t-test for paired data,
as appropriate, for continuous variables. A mixed mode (ME) maximum likelihood linear regression model was
constructed to evaluate the dependence of HCV viral load.
Results: HCV RNA levels did not change significantly from 2009 to 2012 (from 3924650 ± 5320177 IU/ml to 3085128 ±
3372347 IU/ml, p = 0.13); the CD4+ count increased significantly (from a mean of 576 to a mean of 654, p = 0.003). Using
linear regression, a positive correlation was observed for HCV load and genotype 1 (p = 0.002), nonresponder status
(p = 0.04) and with interleukin 28B CC allele (p = 0.05). Other studied covariates failed to reach a significant correlation.
Conclusions: The HCV RNA load, a known pretreatment predictor of response to antiviral therapy, was independent of
the two main parameters of HIV disease, plasma HIV RNA and CD4 cell count, over an observation time of 3 years in
patients with recovered or spontaneously maintained immunocompetence.
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Hepatitis C virus (HCV) is the cause of a significant pro-
portion of cases of chronic liver disease. In human im-
munodeficiency virus (HIV)-HCV co-infected patients
effectively treated with HAART (highly active antiretro-
viral therapy), HCV-related morbidity and mortality has* Correspondence: saverio.parisi@unipd.it
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unless otherwise stated.increased alarmingly in recent years [1]. The treatment
of HCV disease with pegylated interferon and ribavirin
is challenging in HIV-positive patients, but reductions in
liver-related and liver-independent mortality have been
demonstrated in patients who achieved sustained viro-
logical response (SVR) [2]. The efficacy of therapy with
pegylated interferon and ribavirin is lower than in mono-
infected patients; the SVR rates are 38% in naïve patients
and 28% with retreatment [3,4]. Ideally, the timing of HIV
and HCV therapies must be individualized and tailoredtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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can change with time; this approach is especially recom-
mended for HIV patients with HCV genotype 1 infection,
who may be candidates for antiviral treatment, including
direct-acting antiviral drugs (DAAs) [5].
A low pretreatment HCV RNA load is a known positive
factor of SVR [6]. The recently published European AIDS
Clinical Society Guidelines stated that a low pretreatment
HCV RNA value is 400,000-600,000 IU/mL [7]. A pre-
treatment HCV RNA viral load < 600,000 IU/ml is signifi-
cantly associated with SVR in co-infected patients treated
with pegylated interferon and ribavirin (p < 0.001) [8], even
in subjects with compensated cirrhosis (p = 0.01) [9]; con-
versely, a value higher than this threshold is a predicting
factor for relapse (p = 0.02) in the study by Rivero-Juarez
et al. [10]. The HCV RNA viral load is thought to play a
role in fields other than antiviral treatment; Kirk et al. [11]
reported a significant correlation between liver fibrosis
and HCV RNA load (p < 0.001) in a cohort of 1176 HCV-
positive subjects (34% with HIV coinfection).
Studies on clinical and viro-immunological correlates of
HCV RNA load in HIV patients reported conflicting re-
sults. In a cross-sectional study by Collazos et al. [12],
HCV RNA load was lower in subjects with undetectable
HIV viremia (6.17 log10 IU/mL versus 6.08 log10 IU/mL,
p = 0.03), whereas Grint et al. [13] demonstrated that only
ongoing HAART is a predictive factor of HCV viral load
stability over time, with an increase of 2.6% per year com-
pared to 27.6% in untreated subjects (p = 0.009). Plasma
HIV viremia is a dynamic variable; patients taking anti-
retroviral therapy (ART) may develop virological break-
through or experience side effects leading to treatment
interruption, and untreated subjects may start antiretro-
viral drugs.
In this work, we investigate whether HCV viral load
(quantified at the beginning and at the end of the study) is
associated with the demographic, clinical and virological
characteristics of HIV-HCV-co-infected patients. We per-
formed HCV RNA analysis, both as a continuous value
and as a discrete variable (low HCV RNA when viral load
was lower than 600,000 IU/ml).
Results
A total of 1497 patients with HIV infection were followed
at the Infectious Disease Unit of Padova Hospital in Italy
in 2012. In 373 subjects, a diagnosis of HCV co-infection
was reported. A complete description of the selection
process is summarized in Figure 1.
The majority of the patients were Caucasian (80/82,
97.6%). Genotype 3 infection was the most frequent non-
type 1 infection (20 patients, 24.4%), 12 patients (14,6%)
had genotype 4 and only 2 subjects had genotype 2 (2.4%).
The diagnosis of advanced liver fibrosis was based on clin-
ical and not invasive evaluation in most patients; Overall aliver biopsy was performed in only 10 patients (12.2%).
The diagnosis of advanced liver fibrosis was performed by
invasive evaluation only in one patient, liver stiffness data
were available for 8 out the 19 patients (42.1%). Among
the 17 patients who did not achieve an SVR, 8 (47%) had
an HCV genotype 1 infection. The baseline characteristics
of the included patients are described in Table 1.
At the end of the study period, 73 patients were on
ART. In 63 subjects (86.3%), no treatment interruption
was reported. Among subjects who never stopped ART,
successful HIV viremia suppression was observed in
37/63 (58.7%) A total of 14/82 (17.1%) patients showed
HIV RNA suppression in only one of the two periods
included in the IFU. Among these 14 patients, 9 of the
11 subjects with ongoing ART achieved successful HIV
RNA suppression during FFU; thus, the overall percent-
age of treated subjects with successful suppression at
the end of the study period was .46/63 (73%). A detailed
description of the 2012 antiviral regimen is reported
in Figure 2.
The CD4+ count increased significantly from T1 to
T2, with a mean increase of 78 cells/mm3 (from 576 to
654 cells/mm3, p = 0.003), and the T2 value correlated
positively with the T1 count (p = 0.0001). Undetectable
plasma HIV viremia at IFU predicted HIV RNA suppres-
sion at FFU (p = 0.0001) and was positively correlated with
the CD4+ cell count at T2 (p = 0.03). Undetectable plasma
HIV viremia at IFU was correlated with the CD4+ cell
count at T1 (p = 0.04). The HCV RNA level did not
change significantly during the observation period (p =
0.71). In 11 (13.4%) patients a low HCV RNA viral load was
reported both at T1 and T2 and in 22 (26.8%) subjects only
at T1. Low HCV RNA viral load at T1 had a positive asso-
ciation with low HCV RNA at T2 (p = 0.001) and a negative
correlation with the CD4+ cell count at T2 (p = 0.01).
The ME linear regression revealed significant positive
correlations between log10 HCV RNA and HCV genotype
1 (p = 0.002), previous failed HCV treatment (p =0.04) and
harboring the IL28B CC allele (p = 0.05). All other ex-
planatory covariates failed to reach significant P values, in-
cluding the successful suppression of HIV viremia or
persistent ongoing viral replication (irrespective of the
study period analyzed) and ongoing ART at the end of
follow-up (Table 2). The predicted HCV viremia mar-
gins after ME linear regression were calculated, includ-
ing the three significant predictors of high HCV viral
load (Table 3).
Discussion
The objective of this longitudinal study was to analyze
the possible influences of clinical and virological param-
eters on plasma HCV replication evaluated at the begin-
ning and at the end of a time interval of 3 years. Our
data indicate that age, gender, a diagnosis of advanced
1497 HIV positive patients  
373 patients 
with HIV-HCV infection 
243 patients  
with positive HCV RNA  
82 patients  
included in the study 
113 patients with negative HCV 
RNA (67 for spontaneous clearance 
and 46 for SVR) 
17 patients with ongoing antiviral 
therapy or follow-up 
58 patients with severe 
comorbidities 
10 patients with positive HBsAg 
18 patients with antiviral therapy 
stopped after June 2008 
75 patients lacking of regular 
follow-up for HIV disease 
Figure 1 Flow chart describing the selection of the study patients.
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apy, leading to undetectable plasma virema, failed to ex-
hibit significant effects on HCV RNA levels.
Furthermore, we focused our interest on the character-
istics of HIV-HCV-co-infected patients with persistent
serum HCV RNA levels lower than 600,000 IU/ml. Co-
infected patients with persistent low HCV RNA levels
are typically infected with non-genotype 1 viruses and
represent a small proportion (13.4%) of our populationof HIV-HCV-co-infected subjects. However, when only
baseline data are considered, the proportion of co-
infected patients increased to 26.8%, a figure comparable
to the 25% reported in the study by Rallon et al. [14] in
a cohort of 196 co-infected patients. The association be-
tween HCV genotype 1 and the IL28B C allele with
higher HCV RNA values is described in HIV-HCV-co-
infected patients [11,15]; these findings demonstrated
that no unintended selection bias occurred.
Table 1 Demographic, clinical and virological features of
the 82 HIV-HCV co-infected patients who fulfilled the
inclusion criteria
Variables Results
Age (years)1 48 (±6)
Male, n (%)2 62 (75.6)
HCV Genotype 1, n (%)2 48 (58.5)
Previous HCV therapy, n (%)2 17 (20.7)
Advanced liver fibrosis, n (%)2 19 (23.2)
CD4 cell count at T11 (cells/mm3) 576 (±280)
CD4 cell count at T21 (cells/mm3) 654 (±351)
HCV RNA at T11 (IU/ml) 3924650 (±5320177)
HCV RNA at T21 (IU/ml) 3085128 (±3372347)
Ongoing ART at T22, n (%) 73 (89)
Clean IFU, n (%)2 39 (47.6)
Clean FFU5, n (%)2 57 (69.5)
Discordant HIV RNA suppression at IFU4, n (%) 14 (17.1)
IL 28B CC genotype, n (%)2 20 (31.7)
1mean and SD; 2absolute number and percentage respect to all included patients.
ART: Anti Retroviral Therapy; Clean IFU: HIV viremia undetectable during initial
follow-up (0-24 months from T1), regardless of being on ART; Clean FFU: HIV
viremia undetectable during final follow-up (24-36 months from T1), regardless
of being on ART.
Data on IL28B genotype were available for the 63 patients (76.8%).
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co-infection are more likely than HIV-negative subjects to
experience variations in HCV RNA load greater than 0.5
log over a mean period of 43 months. The number of pa-
tients surveyed was greater than that in our study (644
versus 82), but the proportion of patients on ART was
similar to ours (82% and 86.7%, respectively). Only two
HCV RNA controls were available in our study because
there was no clinical indication to prompt more frequent
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Figure 2 Antiretroviral drug regimens of the 73 co-infected patients t
drug combination are reported both percentage respect to the number
AZT = zidovudine; FTC = emtricitabine; MVC = maraviroc; NNRTI = non-nu
RLT = raltegravir; TDF = tenofovir; 3TC = lamivudine.both the baseline and the final mean HCV RNA values for
the patients categorized as having low-level viremia would
correspond to values below 800,000 IU/ml, the threshold
accepted as “low” [17]; therefore, our patients maintained
their virological classification throughout the study period.
Most included patients (76.8%) were on ART, but a per-
sistent undetectable HIV RNA load with a cut-off of 50
copies/ml was observed in only 58.7% of patients. At a
comparable end point (144 weeks of follow-up), the cross-
study analysis by Hua et al. [18] on 279 HIV-HCV-naïve
co-infected patients described a rate of virological failure
(defined as plasma HIV viremia > 200 copies/ml) of 10.5%
(4 patients out of 38 evaluable patients). Of note, HCV sta-
tus was defined only serologically and not by the presence
of detectable HCV RNA, and HBsAg-positive patients
were included, albeit the percentage was low (4.3%). ART
efficacy was not the purpose of our work; nevertheless, we
can report an interesting finding on the long-term efficacy
in a small but homogeneous cohort of all HCV patients
positive for HCV RNA, with no HBV coinfection and of
Caucasian ethnicity who were treated according to the up-
dated HIV guidelines.
Grint et al. [13] described HCV viral load changes in
1541 patients selected from the EuroSIDA study cohort:
the median follow-up was five years, and the only factor
able to stabilize HCV viral load was ART. In this study,
1148 subjects (74.5%) were on ART at baseline, with un-
detectable HIV RNA levels in 657 patients (57.2%); 393
subjects were not taking ART (88.2% with a detectable
HIV RNA). Despite this virological picture, the absence
or presence of detectable plasma HIV viremia has no
significant influence on HCV RNA viral load. Successful
ART and undetectable HIV plasma viremia are obvi-
ously strictly related if we exclude long-term non-
progressing patients. We considered our patients to be




reated in 2012 (data available for 70/73 patients, 95.6%): for each
of treated patients and absolute number. Legend: ABC = abacavir;
cleoside reverse transcriptase inhibitors; PI = protease inhibitor;
Table 2 Mixed mode (ME) maximum likelihood linear regression model test with log10 HCV RNA as dependent variable
Log10 HCV RNA Coef. Std. Err. z P 95% Conf. Interval
Age 0.011 0.021 0.50 0.614 -0.030 0.051
Gender 0.068 0.194 0.35 0.727 -0.313 0.448
HCV genotype 1 0.543 0.178 3.04 0.002 0.194 0.893
Advanced liver fibrosis -0.183 0.205 -0.89 0.372 -0.585 0.219
ART -0.175 0.284 -0.62 0.537 -0.731 0.381
CD4 cell count/mm3 0.000 0.000 -0.21 0.831 -0.001 0.000
Previous HCV therapy 0.378 0.185 2.05 0.041 0.016 0.740
IL28B CC genotype 0.331 0.168 1.96 0.050 0.001 0.660
_cons 5.229 1.047 5.00 0.000 3.178 7.281
Log likelihood = -95.223521, Wald chi2(8) = 18.96, P = 0.0151.
ART: Anti Retroviral Therapy; Clean IFU: HIV viremia undetectable follow-up, regardless of being on ART.
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et al.); however, such a threshold identifies a clinically
successful suppression but does not indicate definitively
absent plasma HIV replicative activity. There is mounting
evidence on the prognostic role of HIV residual viremia
(2.5-50 copies/ml) [19], and we cannot exclude the possi-
bility that residual viremia may influence HCV RNA viral
load, as could greater HIV burden. No correlation was ob-
served between CD4+ cell count and HCV RNA values as
previously described [12]; CD4+ cell count increased from
T1 to T2 (mean increase of 78 cells/mm3, p = 0.003). The
baseline immunocompetence in our enrolled patients was
greater than that reported for subjects in the study by
Grint et al. 576 cells/mm3 versus 340 cells/mm3 in the
subjects on ART [13].
Interestingly, low HCV RNA viral load at T1 was nega-
tively correlated with CD4+ cell count at T2 (p = 0.01).
This finding does not contradict our other data because it
was described in a selected population of patients: those
with low HCV RNA viral load. This report is the first to
describe this correlation, and only speculative hypotheses
can be made, including the inverse correlation between
CD4 cell apoptosis and serum HCV RNA [20].
There is a growing evidence of a low rate of prescrip-
tion of antiviral treatment in co-infected patients. TheTable 3 Predicted HCV viremia, margins after ME linear regre









Three predictors were included, HCV genotype 1, previous anti HCV therapy, and ILstudy by Ioannou et al. [21] reported that only 994 out
of 5999 (18%) HIV-HCV-co-infected patients assisted by
the Veterans Affairs healthcare system received an
interferon-based regimen. This percentage rises to 25.3%
in the EuroSIDA cohort but is accompanied by a reduc-
tion in treatment incidence in 2009 [22]. The proper
timing at which to begin pegylated interferon and ribavi-
rin treatment, associated with DAA when indicated,
must take HIV disease status into account, but such co-
ordination is not an easy task. Concomitant ART may
be a risk factor for the development of side effects even
in the case of therapy with pegylated interferon and riba-
virin without DAA; However, a CD4+ cell number
greater than 450/mmc predicts SVR in co-infected pa-
tients with HCV genotype 1 [23,24].
Conclusions
The strengths of this study can help treating physicians to
tailor the beginning of HCV disease treatment because we
demonstrated that HCV RNA value, a known pretreatr-
ment predictor of response to antiviral therapy, remain in-
dependent of the two main parameters of HIV disease,
plasma HIV RNA detectability and CD4+ cell count, over
an observation time of 3 years and in patients with recov-
ered or spontaneously maintained immunocompetence.ssion









28=CC, in all combinations.
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HIV-HCV co-infected patients
We retrospectively enrolled patients into the study on the
basis of the following eligibility criteria: 1) older than
18 years; 2) diagnosis of chronic HIV infection in 2009; 3)
diagnosis of chronic HCV infection with a detectable
plasma HCV RNA in 2009 and 2012; 4) hepatitis B serum
antigen (HBsAg)-negative in 2009 and 2012; 5) HCV
therapy-naïve or with failed and stopped antiviral treat-
ment before June 2008; 6) regular viro-immunological
follow-up of HIV disease from 2009 to 2012; 7) no preg-
nancy at the time of enrollment and throughout the time
of the study; and 8) no severe comorbidities.
Severe comorbidities were defined as any pathological
condition reported to increase HCV RNA load (i.e.,
intravenous drug use or alcohol abuse).
The enrolled subjects gave informed consent for all pro-
cedures and for the use of their blinded data for scientific
evaluation and publication. This study was conducted in
accordance with the Helsinki Declaration and local legisla-
tion and was approved by the local Ethics Committee.
Throughout the study period, the patients were un-
treated for HIV infection or received antiretroviral treat-
ment according to the current international guidelines.
Decisions on HIV therapy were at the discretion of the
treating physician; there were no restrictions on CD4+
cell counts in 2009 and 2012.
Study time
Two time periods were identified: Initial Follow-Up
(IFU) and Final Follow-Up (FFU). IFU started at T1 (in
2009) and lasted 2 years. The end of IFU coincided with
the start of FFU, a one-year period closer to the end of
the study, which finished at T2, in 2012 (Figure 3).
Study of HIV infection
Plasma HIV-1 RNA levels were measured from blood
samples at all visits (every three months at least). The
lower limit of detection of the commercial test changed0-3 3-6 6-12 12-15 15-18 18-2
T1 
HCV RNA




Initial Follow-Up  (IFU) 
Figure 3 Study design overview. Initial Follow-Up (IFU) started at T1 (in 2
IFU, lasted one year and finished at T2, in 2012.over the course of the study from 20 to 40 copies/mL, but
we considered plasma HIV viremia as undetectable when
the viral load was below the limit of 50 copies/ml [25].
Patients were classified as having undetectable HIV
viremia if no plasma value exceeded 50 copies/ml; only a
single viral blip throughout every year (an increase in
the HIV RNA plasma viral load above 50 copies/ml but
lower than 500 copies/ml and followed by undetectable
HIV RNA) was tolerated [26].
HIV viremia was classified as detectable if any other re-
sult occurred. The detectability of HIV viremia was ana-
lyzed for each period of 12 months and was categorized as
successful suppression or no suppression. Patients who re-
ported different results in the HIV viremia control during
the two 12-month periods included in IFU were considered
to exhibit no HIV RNA suppression, with the aim of clearly
identifying the cohort of HIV-HCV-co-infected patients
with persistent plasma HIV RNA levels < 50 copies/ml.
Patients were classified as taking ART in 2012 when
the HCV RNA was measured if the treatment had been
ongoing for at least three months.
Study of HCV infection
A diagnosis of advanced liver fibrosis was made when a
liver biopsy revealed a result corresponding to Metavir
scores F3 and F4 or when liver stiffness measured by a
transient elastography by FibroScan (Echosens, Paris,
France) had a value higher than 9.5 Kpa [27]. If these data
were not available the estimation of hepatic fibrosis was
made on clinical, laboratory and ultrasound data as de-
scribed by Pineda et al. [28]. Therapy with pegylated inter-
feron and ribavirin was not started during the study time
because of the lack of urgent indication or due to patient
refusal. Previously failed antiviral treatment included ther-
apy with interferon (standard or pegylated) as monother-
apy or with ribavirin according to the current international
guidelines at the moment of treatment start. Any viro-
logical response different from SVR was classified as no re-
sponse to antiviral treatment.1 21-24 24-27 27-30 30-33 33-36
T2 
HCV RNA 
CD4 cell count 
HIV RNA 
2012 
Final Follow-Up  (FFU) 
009) and lasted 2 years, Final Follow-Up (FFU) started at the end of
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HCV RNA genotypes were determined using the VER-
SANT® HCV genotype 2.0 assay (INNOLiPA, Innogenetics,
Belgium). HIV and HCV plasma viral loads (copies/ml)
were evaluated using different platforms: until July 2011
with the COBAS TaqMan assay (Roche, Basel, Switzerland)
and thereafter using the Abbott RealTime assay (Abbott
RT), (Abbott Molecular Inc., Des Plaines, IL).
Interleukin (IL)28B polymorphism genotyping at single-
nucleotide polymorphism locus rs12979860 was con-
ducted using a validated in-house method. The IL28B
allele was classified as CC or not CC (including CT and
TT) for statistical analysis.Statistical analysis
The following variables were recorded: age, gender, HCV
genotype 1 (binary, HCV genotype 1 versus non-genotype
1), IL28B CC genotype (binary, CC genotype versus CT/
TT genotypes), previously failed anti-HCV treatment ver-
sus naïve to antiviral therapy (binary, yes versus no), ad-
vanced liver fibrosis (binary, presence versus absence of
advanced liver fibrosis), antiretroviral therapy (binary, on-
going versus no antiretroviral therapy ongoing at T2),
CD4+ cell count at T1 and at T2, HCV viral load at T1
and at T2, IFU HIV RNA levels (binary, bad versus good
HIV RNA suppression) and final follow-up HIV RNA
levels (binary, bad versus good HIV RNA suppression).
Moreover, the following derived variables were obtained:
log10 HCV RNA at T1 and log10 HCV RNA at T2 after
log10 transformation of T1 HCV RNA and T2 HCV RNA,
respectively.
The variables were submitted to pairwise correlation
analysis to outline the underlying pattern in the evaluated
population. The correlation was established using linear
regression analysis, analysis of variance (ANOVA) and
Fisher’s exact test. Comparisons between groups were per-
formed using Fisher’s exact test, the independent samples
t-test and the t-test for paired data, as appropriate, for
continuous variables.
A mixed mode (ME) maximum likelihood linear regres-
sion model was constructed. The following time-varying
covariates were obtained: CD4+ cell count, logHCV
viremia and successful HIV viremia suppression. The de-
pendence of HCV viral load on a set of time-invariant
(age, gender, HCV genotype 1, advanced liver fibrosis, pre-
vious failed HCV therapy) and time-varying covariates
was established. The limit of significance for all analyses
was established at p < 0.05.
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